EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Anavex Life Sciences's enterprise value is $136.24 Mil.
Anavex Life Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Anavex Life Sciences's EV-to-Revenue for today is .
The historical rank and industry rank for Anavex Life Sciences's EV-to-Revenue or its related term are showing as below:
AVXL's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.68 * Ranked among companies with meaningful EV-to-Revenue only.
Anavex Life Sciences EV-to-Revenue Historical Data
The historical data trend for Anavex Life Sciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Anavex Life Sciences's EV-to-Revenue
For the Biotechnology subindustry, Anavex Life Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's EV-to-Revenue falls into.
Anavex Life Sciences's current Enterprise Value is $136.24 Mil.
Anavex Life Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences (NAS:AVXL) EV-to-Revenue Explanation
Anavex Life Sciences's share price for today is $3.39.
Anavex Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Anavex Life Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Anavex Life Sciences (Anavex Life Sciences) Business Description
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVXL has been successfully added to your 